Glenmark Pharma gains as its arm to launch Ropivacaine Hydrochloride Injection
Glenmark Pharmaceuticals is currently trading at Rs. 1873.20, up by 17.50 points or 0.94% from its previous closing of Rs. 1855.70 on the BSE.
The scrip opened at Rs. 1870.00 and has touched a high and low of Rs. 1878.00 and Rs. 1853.85 respectively. So far 4298 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2286.15 on 11-Jul-2025 and a 52 week low of Rs. 1274.70 on 28-Feb-2025.
Last one week high and low of the scrip stood at Rs. 1977.25 and Rs. 1860.05 respectively. The current market cap of the company is Rs. 52722.17 crore.
The promoters holding in the company stood at 46.65%, while Institutions and Non-Institutions held 39.38% and 13.97% respectively.
Glenmark Pharmaceuticals’ US-based subsidiary -- Glenmark Pharmaceuticals Inc., (Glenmark) is all set to launch Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials. Glenmark’s Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials is bioequivalent and therapeutically equivalent to the reference listed drug, Naropin 2 Injection, 40 mg/20 mL (2 mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL), of Fresenius Kabi USA, LLC NDA - 020533. Glenmark will begin distribution in November 2025.
According to IQVIA sales data for the 12-month period ending August 2025, the Naropin Injection, 40 mg/20 mL (2 mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) market achieved annual sales of around $20.9 million.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
